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ABSTRACT
Objectives: Systemic mastocytosis (SM) is a myeloproliferative disease characterized by the
accumulation of aberrant mast cells. Since advanced subtypes of SM can lead to organ
dysfunction and shortened survival, timely recognition of progressive disease is important for
the adequate treatment of SM patients.
Methods: Here, we report the results of our cohort study on the value of routine abdominal
ultrasonography for the detection of progression of indolent systemic mastocytosis (ISM).
Results: We included 88 patients with ISM, of whom 9 developed new hepatosplenomegaly
during follow-up. In this group, the median serum tryptase level increased by 11.60 μg/l,
compared with a decrease of −0.20 μg/l in the 79 patients with unchanged ultrasonography
results (p = 0.016). A change in liver and/or spleen size never led to a change in clinical
classification, nor management.
Discussion: Based on the finding that a change in ultrasonography findings did not correlate to
disease progression in general, it appears that isolated hepatosplenomegaly does not have
prognostic implications in patients with ISM.
Conclusions: Routine abdominal ultrasonography is redundant in the follow-up of patients with
ISM. A combination of physical examination with serum tryptase levels can be used to screen for
hepatosplenomegaly.
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Introduction
Mastocytosis is a rare myeloproliferative disease in
which there is uncontrolled proliferation of aberrant
mast cells [1]. The World Health Organisation (WHO)
distinguishes cutaneous from systemic mastocytosis
[2]. Systemic mastocytosis (SM) is further divided into
different subtypes, each having their own criteria, clini-
cal manifestations and prognosis [3,4]. Indolent sys-
temic mastocytosis (ISM) is the most common
subtype which has a favourable prognosis, with
patients mainly suffering from mast cell mediator-
related symptoms. More recently, it was recognized
that the clinical symptoms of ISM patients with skin
lesions are distinct from the ISM patients without skin
lesions (ISMs+ vs. ISMs−, respectively) [5]. In contrast
to ISM, advanced subtypes are characterized by
organ infiltration by mast cells (smouldering SM and
aggressive SM), or a second haematological (non-
mast cell) neoplasm (SM-AHN). To diagnose smoulder-
ing SM, 2 or more B-findings have to be present:
hepato- or splenomegaly, lymphadenopathy, >30%
mast cell infiltration of bone marrow, a serum tryptase
level >200 μg/l, or signs of dysplasia without reaching
criteria for myelodysplastic syndrome. For aggressive
SM, C-findings were formulated: cytopaenia, signs of
liver cirrhosis, malabsorption or osteolytical bone
lesions. The difference between smouldering and
aggressive SM is the respective absence or presence
of organ dysfunction. These advanced subtypes can
shorten survival and often warrant cytoreductive treat-
ment [4,6]. Hence, an important goal of outpatient
follow-up of ISM patients is to screen for progression
of the disease or development of a second haematolo-
gical disease [3]. There is some evidence that radiologi-
cal examination of the abdomen can aid in
determining the extent of systemic involvement of
SM [7]. For these reasons, a consensus group of
Dutch physicians with expertise in mastocytosis pre-
viously decided to routinely perform abdominal ultra-
sonography in the follow-up of SM patients. In the
Erasmus University Medical Centre, it was common
practice to perform abdominal ultrasonography every
2–3 years to screen for hepatosplenomegaly.
However, new data show that progression of indolent
to advanced SM is rare, and it is unclear what would
be the best method to screen patients with ISM for pro-
gression. Moreover, in this era where health care costs
are an important societal issue, it is important to cut
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down unnecessary tests. The objective of this study
was, therefore, to determine the value of routine
abdominal ultrasonography as a tool to screen for pro-
gression of indolent to more aggressive forms of SM.
Methods
Patient selection and data collection
We selected all adult patients who visited the Erasmus
University Medical Centre from January 2009 to Febru-
ary 2016 and who fulfilled the WHO criteria for ISM [2].
Only patients who underwent at least two abdominal
ultrasonographies, with a minimal interval of 2 years,
were included. Patients who had SM-AHN or ASM at
baseline were excluded. All patients visited the outpa-
tient clinic at least once a year. Bone densitometry was
performed every 3 years to screen for osteoporosis. We
retrospectively collected the findings on abdominal
ultrasonography, as well as data on patient baseline
characteristics, SM subtype and symptoms, tryptase
levels, and bone densitometry results from the elec-
tronic patient charts.
Definitions
Hepatosplenomegaly was defined as either a craniocau-
dal liver size of >15 cm, and/or a spleen size of >11 cm.
A change in ultrasonography findings was defined as
a change from a normal size to hepatosplenomegaly
on subsequent examinations, or vice versa. Cytopaenia
was defined as either anaemia (Hb < 10 g/dl),
leukopenia (<400 × 106) and/or thrombocytopenia
(<1000 × 106). Skin involvement was described as all
forms of maculopapular cutaneous mastocytosis
(MPCM) [8].
Statistical analysis
We constructed two groups, according to their course of
ultrasonography results. The primary endpoint was pro-
gression from indolent to smouldering, aggressive or
SM-AHN, or progression from smouldering to aggressive
or SM-AHN. We used IBM SPSS statistics 21 for all ana-
lyses. The Mann–Whitney U-test was used for the com-
parison of the tryptase values and unpaired t-tests
were used for continuous variables. The chi-square test
was used for dichotomous variables.
Results
Study population
Of a total of 154 patients, 95 underwent multiple
abdominal ultrasonographies with an interval of >2
years. Seven patients were excluded because they ful-
filled the WHO criteria for ASM or SM-AHN at baseline.
Figure 1 summarises the selection process. The popu-
lation we analysed thus consisted of 88 patients, of
whom 81 had ISM and 7 patients had smouldering
SM. Ten of these 88 patients had a change in liver
and/or spleen size over time, 9 of whom newly devel-
oped hepatosplenomegaly (10.2% of the total
Figure 1. Flow chart of the inclusion process.
2 C. L. DE MOL ET AL.
population). The liver and spleen size normalized in
one patient. The median follow-up time was 11.20
years.
Group characteristics
We divided the population into two groups, entitled
‘unchanged hepatosplenomegaly status’ and ‘new hepa-
tosplenomegaly’. Baseline characteristics and follow-up
data are summarized in Table 1. The patient with normal-
ization of liver/spleen size was included in the
‘unchanged hepatosplenomegaly status’ group. The
age of the patients did not differ significantly between
the two groups. Two patients in the ‘unchanged hepa-
tosplenomegaly status’ group had cytopaenia at base-
line. No one had other B- or C-findings. The
development of hepatosplenomegaly during follow-up
was not associated with a decrease in bone density.
Follow-up findings
The median change in serum tryptase level during
follow-up was −0.20 μg/l (SD 28.3) for the ‘unchanged
hepatosplenomegaly status’ group, versus an increase
of 11.60 μg/l (SD 26.2) in the ‘new hepatosplenome-
galy’ group. When comparing the change in tryptase
levels over time, a significant difference was found
between the patients who newly developed hepatos-
plenomegaly compared with the patients with
unchanged ultrasonography findings (p = 0.016). In
the patients who newly developed hepatosplenome-
galy, there was no statistically significant change in
liver enzyme levels (mean increase in ASAT levels of
4 U/l (SD 11.86 U/l), mean increase in ALAT levels of
7.5 U/l (SD 22.05 U/l)).
Of the patients with ‘unchanged hepatosplenome-
galy status’, 12 (15.2%) had hepatosplenomegaly at
baseline which did not change during follow-up.
These patients did not develop clinical signs of liver
cirrhosis during follow-up, nor did they show other
signs of progression of mastocytosis. Accordingly,
serum tryptase levels remained relatively stable with
a median decrease of –1.15 μg/l (SD 48.0 μg/l) in this
subgroup.
One patient in the unchanged group went from ISM
s+ to smouldering SM over time, based on a serum
tryptase level of >200 μg/l and >30% bone marrow
infiltration by mast cells. This patient had no hepatos-
plenomegaly. A change in liver and/or spleen size
alone never led to a change in SM subtype, nor in a
change in the medical management. One patient
showed normalization of his liver size and spleen size.
This patient was treated with imatinib because of
extensive skin lesions. In this patient, the KIT D816 V
mutation was detected and his tryptase value
increased by 6.0 μg/l during follow-up.
Discussion
This study shows that routine abdominal ultrasonogra-
phy has limited value in the follow-up of patients with
indolent systemic mastocytosis: 10.2% developed new
hepatosplenomegaly, but no one showed progression
to a more advanced type of SM. The development of
new hepatosplenomegaly had no clinical consequences
in any of them. Until this study, abdominal ultrasonogra-
phy was part of the routine follow-up in the Erasmus
University Medical Centre to screen for progression of
ISM. However, it has become clear that progression of
ISM is very rare [3,9]. Our results confirm this, as only
one patient (1.1%) progressed from indolent to smoul-
dering SM in a median follow-up time of 11.20 years.
Moreover, this patient did not develop hepatospleno-
megaly. Furthermore, patients who had hepatospleno-
megaly at baseline did not develop clinical signs of
liver cirrhosis, or progression of mastocytosis in
general. Based on these findings, we hypothesize that
the finding of isolated hepatosplenomegaly, without
Table 1. Patient characteristics, divided according to ultrasonography findings.
Unchanged status of
hepatosplenomegaly (n = 79)
New hepatosplenomegaly
(n = 9) p-value
Age in years (median, SD) 58.00 (12.89) 54.00 (9.94) NS
Male sex (n, %) 35 (44.3%) 3 (33.3%) NS
Follow-up time in years (median, SD) 10.00 (6.76) 12.00 (3.24) NS
Subtype of SM N/A
ISM s− 17 2
ISM s+ 56 6
SSM 6 1
Absolute change in serum tryptase levels in μg/l
(median, SD)
−0.20 (28.3) 11.60 (26.2) 0.016
Change in subtype (n) 1 0 N/A
Change in treatment (n) 0 0 N/A
Cytopaenia at baseline (n, %) 2 (2.5%) 0 (0%) NS
Decrease in bone density during follow-up (n, %) 11 (13.9%) 0 (0%) NS
Presence of KIT D816V mutation (n, %) 36 (45.5%) 4 (44.4%) NS
Presence of lymphadenopathy (n, %) 4 (5.1%) 0 (0%) NS
Note: SD: standard deviation; SM: systemic mastocytosis; ISM s−: indolent systemic mastocytosis without skin lesions; ISM s+: indolent systemic mastocytosis
with skin lesions; SSM: smouldering systemic mastocytosis; SM-AHN: systemic mastocytosis with associated haematological neoplasm; ASM: aggressive
systemic mastocytosis; NS: non-significant, N/A: not applicable.
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other B- or C-findings, does not have important prog-
nostic implications. Therefore, looking for hepatospleno-
megaly is probably not appropriate when screening for
progression of disease in ISM. Moreover, badly indicated
radiologic investigations lead to higher health care costs,
and a risk of unwanted incidental findings [10].
Interestingly, the median serum tryptase level increased
significantly in patients who newly developed hepatos-
plenomegaly, whereas they remained stable in patients
with unchanged ultrasonography findings. Besides the
serum tryptase level, there were no other signs of
progression of disease in all patients but one who
progressed from indolent to smouldering SM. More
specifically, patients did not develop other B- or C-find-
ings. In another study, serum tryptase levels did corre-
late to clinical progression in general, and patients
with rising serum tryptase levels more often developed
hepatosplenomegaly [11]. It would be interesting to
know whether the hepatosplenomegaly truly is mast
cell related; however, this would require biopsies of
both organs which is a risky procedure and not feasible
in this context. Furthermore, MR elastography or fibros-
can could be of additional value to estimate a risk of liver
cirrhosis in the future. Unfortunately, we have not per-
formed these investigations routinely and cannot
provide data on this yet [12].
To our knowledge, our study is the first to focus on
the value of routine abdominal ultrasonography in the
screening for progression of disease in ISM patients.
However, our results should not be extrapolated to
patients with advanced subtypes of SM. Follow-up
abdominal ultrasonography can be indicated in
advanced SM for other reasons. One limitation of this
study is the retrospective nature, which could have
led to incomplete data. We had to exclude 59 patients,
because they did not have >2 abdominal ultrasonogra-
phies during follow-up. This could have led to a selec-
tion bias, although the fact that their physician did not
order more ultrasonographies probably implies that
they estimated the risk of progression as low. In that
scenario, our results would not have changed with
inclusion of these patients. Moreover, the retrospective
design provides ‘real-life’ data and a long follow-up
time. Lastly, ultrasonography, in general, has a notor-
iously large inter-test variability and one can argue
whether subtle cases of hepatosplenomegaly were
missed by using this technique [13].
In conclusion, routine abdominal ultrasonography
has limited value as a screening tool for progression
of ISM. It appears that isolated hepatosplenomegaly
has no important prognostic implications in ISM, and
changes in liver and/or spleen size alone, in fact,
never herald progression of SM. Moreover, progression
of indolent to advanced SM is very rare. Annual
follow-up of serum tryptase levels could be used as
a first screening tool for the development of
hepatosplenomegaly, with additional radiologic
studies on indication.
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